Company: TELO
Filing Date: 2025-05-14
Form Type: 10-Q
Source: 0001641172-25-010298
Chunk: 14

Company: Telomir Pharmaceuticals, Inc.
Filing Date: 2025-05-14
Form: 10-Q
Item: Item 8
Chunk 14
---
-1 is intended to support metal homeostasis,
reduce oxidative imbalance, and help preserve telomere integrity. This approach is based on emerging research indicating that metal ion
dysregulation can accelerate oxidative stress and contribute to cellular decline. Preclinical studies have shown that Telomir-1 may influence
pathways involved in telomere maintenance and cellular protection, supporting its potential as a therapeutic candidate for further development
in age-related conditions.

To
date, we have not generated any revenue nor do we expect to generate revenue unless and until we successfully complete preclinical and
clinical development of, receive regulatory approval for, and commercialize a program and we do not know when, or if at all, that will
occur. We expect our expenses to increase substantially in connection with our ongoing activities, particularly as we advance the preclinical
activities and studies and initiate clinical trials. In addition, if we obtain regulatory approval for any programs, we expect to incur
significant expenses related to production of sales, marketing, and distribution to the extent that such sales, marketing and distribution
are not the responsibility of potential collaborators. We expect to incur additional costs associated with operating as a public company.

We
had net losses of $2.2 million and $6.3 million for the three months ended March 31, 2025 and 2024, respectively.

Highlights-Three
Months Ended March 31, 2025

●
On January 7, 2025, we announced a preclinical progeria lifespan study conducted in collaboration with Nagi Bioscience SA. Utilizing
C. elegans (nematode) models, in which the study demonstrated restoration of shortened lifespan and normalization of accelerated aging
with Telomir-1.

●
On January 28, 2025, we announced that our studies demonstrated the ability of Telomir-1 to fully reverse copper-induced elevation of
ROS and provide robust cellular protection against copper toxicity.

●
On February 18, 2025, we announced that our studies had demonstrated the ability of Telomir-1 to significantly reverse copper and iron-induced
elevation of Reactive Oxygen Species (ROS).

●
On February 21, 2025, we announced that Telomir-1 had successfully captured and stabilized both Silver(I) (Ag⁺) and the highly
reactive Silver(II) (Ag²⁺) in a biologically compatible form.

●
On February 26, 2025